Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of ($0.29), $0.14 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $26.97 million versus the consensus estimate of $28.42 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2022 ARCALYST revenue of $115-130 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.